Related Experiment Videos
Cutaneous lymphomas: a proposal for a unified approach to classification using the R.E.A.L./WHO Classification
E S Jaffe1, C A Sander, M J Flaig
1Hematopathology Section, National Cancer Institute, Bethesda, MD, USA. elainejaffe@nih.gov
Summary
A unified classification system for cutaneous lymphomas is recommended. Organ-specific schemes may hinder recognizing common disease features and cause confusion; a single R.E.A.L./WHO Classification is preferred for all lymphomas.
Area of Science:
- Hematology
- Oncology
- Dermatopathology
Background:
- The classification of cutaneous lymphomas remains controversial.
- The European Organisation for Research and Treatment of Cancer (EORTC) proposed a unique system for cutaneous lymphomas.
- Conventional classification schemes have been deemed unsuitable for cutaneous lymphomas.
Purpose of the Study:
- To review the suitability of the R.E.A.L. Classification for cutaneous lymphomas.
- To compare the R.E.A.L. Classification with the proposed EORTC system.
- To advocate for a unified classification system for all lymphomas.
Main Methods:
- Review of the R.E.A.L. Classification principles and their adoption by the World Health Organization (WHO).
- Comparison of the R.E.A.L. Classification with the EORTC proposed system for cutaneous lymphomas.
- Integration of morphology, immunophenotypic and genetic features, clinical presentation, and course in disease definition.
Main Results:
- Organ-specific classification systems may obscure common disease features across different anatomic sites.
- The EORTC Classification for cutaneous lymphomas, while addressing dermatologists' needs, could lead to confusion by introducing multiple systems.
- Cutaneous lymphomas may exhibit more indolent behavior than nodal lymphomas, potentially requiring distinct therapeutic strategies.
Conclusions:
- Organ-specific classification schemes for cutaneous lymphomas are unnecessary and may hinder recognition of shared disease characteristics.
- A unified R.E.A.L./WHO Classification system should be adopted for all lymphomas, irrespective of their site of origin.
- Clinical features, including systemic spread and site of origin, are crucial for prognosticating and guiding therapy for cutaneous lymphomas.